{'52WeekChange': 0.7550268,
 'SandP52WeekChange': None,
 'address1': 'No.30 Science Park Road',
 'address2': 'Zhong-Guan-Cun Life Science Park Changping District',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 241,
 'askSize': 1300,
 'averageDailyVolume10Day': 392375,
 'averageVolume': 280257,
 'averageVolume10days': 392375,
 'beta': 1.295871,
 'beta3Year': None,
 'bid': 224.44,
 'bidSize': 1200,
 'bookValue': 36.272,
 'category': None,
 'circulatingSupply': None,
 'city': 'Beijing',
 'companyOfficers': [],
 'country': 'China',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 226.33,
 'dayLow': 217.343,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -12.616,
 'enterpriseToRevenue': 35.642,
 'enterpriseValue': 14343569408,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 198.97,
 'fiftyTwoWeekHigh': 256.01,
 'fiftyTwoWeekLow': 114.41,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 37782159,
 'forwardEps': -13.8,
 'forwardPE': -16.263767,
 'fromCurrency': None,
 'fullTimeEmployees': 3600,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.2053,
 'heldPercentInstitutions': 0.65331,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/beigene.com',
 'longBusinessSummary': 'BeiGene, Ltd., a commercial-stage biotechnology '
                        'company, develops and commercializes '
                        'molecularly-targeted and immuno-oncology cancer '
                        "therapeutics in the People's Republic of China, the "
                        'United States, and internationally. Its commercial '
                        'products include BRUKINSA to treat R/R mantle cell '
                        'lymphoma; Tislelizumab to treat R/R classical '
                        "Hodgkin's lymphoma; ABRAXANE to treat breast cancer; "
                        'REVLIMID to treat multiple myeloma; VIDAZA to treat '
                        'myelodysplastic syndromes, chronic myelomonocyte '
                        'leukemia, and acute myeloid leukemia; XGEVA to treat '
                        'giant cell tumor of bone; KYPROLIS to treat multiple '
                        'myeloma; BLINCYTO to treat acute lymphocytic '
                        'leukemia; SYLVANT to treat idiopathic multicentric '
                        'castleman disease; and QARZIBA to treat '
                        "neuroblastoma. The company's clinical stage drug "
                        'candidates comprise Zanubrutinib, a BTK inhibitor to '
                        'treat various lymphomas; Tislelizumab, an anti-PD-1 '
                        'antibody to treat various solid and hematological '
                        'cancers; Pamiparib, an inhibitor of PARP1 and PARP2 '
                        'to treat various solid tumors; Lifirafenib and '
                        'BGB-3245 to treat various malignancies, such as '
                        'melanoma, NSCLC, and endometrial cancer; and '
                        'Sitravatinib, a multi-kinase inhibitor to treat '
                        'NSCLC, melanoma, and other solid tumor. In addition, '
                        'its clinical stage drug candidates include BGB-A333, '
                        'a PD-L1 inhibitor to treat various solid tumors; '
                        'BGB-A1217, a TIGIT inhibitor to treat various solid '
                        'tumors; BGB-11417, a small molecule Bcl-2 inhibitor '
                        'to treat mature B-cell malignancies; and BGB-A445, an '
                        'OX40 agonist antibody to treat solid tumors. The '
                        'company has collaborations with Celgene Corporation; '
                        'Merck KGaA; Mirati Therapeutics, Inc.; BioAtla, LLC; '
                        'Zymeworks, Inc.; Ambrx, Inc.; Atreca Inc.; IGM '
                        'Biosciences, Inc.; and Hutchison China MediTech '
                        'Limited. BeiGene, Ltd. was founded in 2010 and is '
                        "based in Beijing, the People's Republic of China.",
 'longName': 'BeiGene, Ltd.',
 'market': 'us_market',
 'marketCap': 20751722496,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_115205344',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -1144722944,
 'nextFiscalYearEnd': 1640908800,
 'open': 226.06,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.57,
 'phone': '86 10 5895 8000',
 'previousClose': 233.05,
 'priceHint': 2,
 'priceToBook': 6.187693,
 'priceToSalesTrailing12Months': 51.565014,
 'profitMargins': -2.84447,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 226.33,
 'regularMarketDayLow': 217.343,
 'regularMarketOpen': 226.06,
 'regularMarketPreviousClose': 233.05,
 'regularMarketPrice': 226.06,
 'regularMarketVolume': 231105,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 89493504,
 'sharesPercentSharesOut': 0.035,
 'sharesShort': 2639011,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 2868261,
 'shortName': 'BeiGene, Ltd.',
 'shortPercentOfFloat': None,
 'shortRatio': 13.48,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'BGNE',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -17.751,
 'twoHundredDayAverage': 166.91573,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'fa34b256-867c-3115-a0ac-dc5f85107a4b',
 'volume': 231105,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.beigene.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '102206'}